Combination therapy before surgery for triple-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted therapies (pertuzumab and trastuzumab) and hormone therapy (palbociclib and exemestane) given before surgery for triple-positive breast cancer. The goal is to see if this package effectively shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 75 years old.
- You must have stage II or stage III breast cancer that is 'triple-positive' — meaning it has both hormone receptors and the HER2 protein.
- Your cancer must not have spread to distant parts of the body (stage IV).
- You must not have had any prior treatment for this breast cancer, such as surgery, chemotherapy, radiation, or hormone therapy.
- Your heart, liver, and kidneys must be working well enough based on routine tests.
- You must have a 'measurable' tumor that can be seen on imaging scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.